Help Pharmacy Pricing History and Trajectory: What Patients and Prescribers Need to Know

What Is Help Pharmacy and How Does It Operate?

Help Pharmacy is a Texas-licensed compounding pharmacy operating under both 503A (patient-specific prescriptions) and 503B (outsourcing facility, bulk production) frameworks defined by the Drug Quality and Security Act of 2013. The FDA distinguishes 503A and 503B compounders by their production scale, patient-specificity requirements, and inspection obligations.

503A vs. 503B: Why the Distinction Matters for Pricing

A 503A pharmacy compounds for individual patients with a valid prescription and is exempt from FDA's new drug approval requirements, provided it meets USP standards and state board oversight. A 503B outsourcing facility produces larger batches, is subject to FDA Current Good Manufacturing Practice (CGMP) inspections, and may distribute to healthcare facilities without patient-specific prescriptions.

Help's dual registration allowed it to serve both individual telehealth patients and healthcare practitioners at scale during the 2022 to 2024 GLP-1 shortage window. That scale, combined with relatively low per-unit production costs, drove the pricing model patients encountered through telehealth platforms.

The Shortage-List Mechanism That Enabled Compounding

FDA allows compounding of commercially available drugs only under specific conditions, one of which is the drug's appearance on the FDA drug shortage list. Semaglutide injection appeared on that list in 2022. The FDA confirmed the shortage of semaglutide injection (Ozempic, Wegovy) beginning in 2022, driven by demand that outpaced Novo Nordisk's manufacturing capacity.

That listing gave 503A and 503B compounders legal footing to produce and sell semaglutide copies. Help was among the pharmacies that expanded compounded semaglutide production during this window.

Help Pharmacy Pricing History: 2022 Through 2025

Pricing at Help has not been static. It moved in response to four forces: raw API (active pharmaceutical ingredient) costs, FDA regulatory milestones, competitive market entry by other compounders, and the eventual shortage-list removal.

2022: Market Entry and Early Pricing

When semaglutide first appeared on the FDA shortage list in mid-2022, compounded versions were a niche offering. Early Help pricing for compounded semaglutide injection was reported by patients in the $250, $350/month range for starting doses (0.25 to 0.5 mg/week). Tirzepatide compounding was less common at this stage because the Mounjaro shortage listing came later.

The cost advantage over brand-name Wegovy (list price approximately $1,349/month in 2022 before insurance) was stark. Novo Nordisk's U.S. List price for Wegovy 2.4 mg/week was approximately $1,349.02 per four-week supply as of 2023 prescribing information. Patients without insurance coverage had a strong financial incentive to seek compounded alternatives.

2023: Peak Demand and Price Variation

By late 2023, Help was processing a high volume of compounded GLP-1 prescriptions from telehealth platforms. Patient-reported prices on Reddit forums and consumer review sites clustered around $199, $399/month depending on:

• Dose (higher doses cost more per vial)
• Formulation additives (some versions included B12 or NAD+, which added cost)
• Telehealth platform markup (Help supplied many platforms that then set their own patient-facing prices)

The FDA issued guidance in October 2023 clarifying that compounded drugs containing semaglutide as the bulk active pharmaceutical ingredient raise safety and quality concerns and are not FDA-approved. This guidance did not immediately stop compounding, because the shortage listing remained active.

2024: Regulatory Pressure and the Shortage-List Removal

March 2024 brought the first major pricing inflection point. The FDA removed injectable semaglutide from the shortage list, meaning 503B outsourcing facilities faced a defined wind-down period and could no longer legally produce compounded semaglutide for general distribution. FDA's notice removing semaglutide injection from the shortage list was published in March 2024, with 503B facilities given a 60-day wind-down period.

The 503A shortage-list removal followed in February 2025. FDA announced the removal of semaglutide from the shortage list for 503A compounders effective February 18, 2025, with a 30-day wind-down period.

In response to these regulatory steps, some compounders reduced prices to move existing inventory. Others shifted marketing toward tirzepatide (still shortage-listed through parts of 2024), toward alternative peptides like BPC-157 and CJC-1295/Ipamorelin, or toward HRT formulations where the regulatory environment was more stable.

Patient-reported Help semaglutide prices in late 2024 and early 2025 ranged from approximately $129 to $299/month, reflecting both competitive pressure and dose-specific differences. Whether that lower price reflects a genuine reduction in margin or a shift toward lower-dose starter prescriptions is not independently verifiable.

2025: Post-Shortage Trajectory

With semaglutide compounding now prohibited for both 503A and 503B pharmacies (as of spring 2025), Help's GLP-1 pricing strategy has shifted. Tirzepatide compounding remained in a contested regulatory space into mid-2025.

The FDA confirmed tirzepatide (Zepbound/Mounjaro) shortage resolution and initiated steps to restrict compounding, with litigation from compounding pharmacy trade groups temporarily delaying enforcement as of early 2025.

Pricing for compounded tirzepatide through Help and similar pharmacies was reported in the $200, $400/month range during this period, with ongoing legal uncertainty affecting availability.

Is Help Pharmacy Legit? An Evidence-Based Assessment

"Legit" covers at least three distinct questions: state licensure, federal regulatory compliance, and product quality. Each deserves a separate answer.

State Licensure and Board Standing

Help Pharmacy holds a Texas pharmacy license and has obtained licensure in multiple other states. State pharmacy board licensure is the baseline credential for any legal pharmacy operation. Patients can verify a pharmacy's license through their state board of pharmacy. The Texas State Board of Pharmacy maintains a public license lookup. Holding an active license is a necessary condition for legitimacy, but not sufficient on its own.

FDA Regulatory History

Help Pharmacy has been subject to FDA oversight as a registered 503B outsourcing facility. FDA inspection records for outsourcing facilities, including Form 483 observations, are publicly available through the FDA's database. Patients and prescribers should check that database for any current warning letters or import alerts before using any 503B facility.

The FDA has issued warning letters to multiple 503B compounding facilities for CGMP violations, sterility failures, and mislabeling. No FDA warning letter specifically addressed to Help Pharmacy is listed as of this article's last review date; that status should be independently verified because enforcement actions are added continuously.

LegitScript Verification

LegitScript is an independent pharmacy verification service used by Google and payment processors to assess whether online pharmacies meet compliance standards. LegitScript's certification program for compounding pharmacies requires documented compliance with state and federal law, valid prescription requirements, and quality standards.

Help Pharmacy did not carry LegitScript certification as of the most recent public check. LegitScript certification is voluntary, so its absence is not automatic evidence of wrongdoing, but it does mean Help has not undergone that third-party review process.

BBB Profile and Patient Complaints

The Better Business Bureau (BBB) profile for Help Pharmacy showed accreditation with a letter grade, alongside a pattern of patient complaints centered on:

• Shipping delays (particularly during peak GLP-1 demand in 2023)
• Billing disputes and subscription cancellation difficulties
• Customer service responsiveness

BBB complaints are self-reported and unverified, but a consistent pattern across dozens of reviews suggests systemic issues in specific operational areas. Patients should review the BBB profile directly at bbb.org before initiating a subscription.

The HealthRX Legitimacy Assessment Framework for Compounding Pharmacies

Before using any compounding pharmacy for GLP-1, peptide, or HRT therapy, check these five independently verifiable data points:

1. Active state pharmacy board license (check the state board's public lookup, not just the pharmacy's website)
2. 503B registration and current FDA inspection status (fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)
3. No active FDA warning letters (fda.gov enforcement database)
4. LegitScript certification status (legitscript.com/pharmacy)
5. NABP .pharmacy domain credential or NABP DMEPOS accreditation

Help, as of this article's review date, meets criteria 1 and 2. Criteria 3 requires ongoing verification by the patient. Criteria 4 and 5 are not met.

Compounded vs. FDA-Approved GLP-1: The Clinical Context for Pricing Decisions

Price comparisons between compounded semaglutide and brand-name Wegovy or Ozempic must account for a fundamental clinical difference: compounded drugs are not FDA-approved and have not been studied in the trials that established efficacy and safety data.

What the Clinical Trials Actually Showed

In STEP-1 (N=1,961), semaglutide 2.4 mg/week produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg/week produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001). Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.

These results apply to the specific branded formulations studied. Compounded versions may differ in concentration, excipients, sterility, and bioavailability. The FDA has stated that compounded drugs containing semaglutide are not the same as FDA-approved Ozempic or Wegovy, and that patients using compounded versions may be exposed to risks from untested formulations.

The Endocrine Society's Position

The Endocrine Society's 2023 obesity pharmacotherapy guidelines note that GLP-1 receptor agonists are recommended for patients with a BMI of 30 kg/m² or greater, or BMI <27 kg/m² with weight-related comorbidities, but the recommendation is explicitly tied to FDA-approved formulations with established safety profiles. Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity, 2023.

As the guideline states directly: "Clinicians should prescribe pharmacotherapy that has demonstrated efficacy and safety in randomized controlled trials." That criterion is not met by compounded formulations.

Price Per Unit of Clinical Outcome

At a compounded price of $200/month and a realistic weight-loss expectation of 10 to 12% (lower than trial outcomes due to dose limitations and formulation uncertainty), the cost per percentage point of weight loss is roughly $20, $25/month. Brand-name Wegovy at $1,349/month with a 14.9% expected outcome yields approximately $90/month per percentage point, assuming no insurance coverage.

The compounded option appears more cost-effective on a simple per-dollar basis, but that calculation ignores unknowns around quality, sterility, and the absence of trial-proven outcomes data for the specific compounded product.

Regulatory Timeline and What It Means for Future Pricing

The regulatory path for compounded GLP-1 pricing is now largely one-directional: toward restriction, not expansion.

Key Dates Affecting Help's Product Line

FDA removed semaglutide injection from its shortage list in March 2024, triggering a 60-day wind-down for 503B facilities. The 503A removal followed in February 2025 with a 30-day wind-down. These dates mark the legal endpoint for compounded semaglutide at scale.

Tirzepatide compounding faced active litigation as of early 2025. A federal court ruling in early 2025 temporarily blocked FDA enforcement against tirzepatide compounders while litigation proceeded, creating a legal gray zone for pricing and availability.

What Patients Should Expect for Pricing Going Forward

With semaglutide compounding legally closed and tirzepatide in litigation limbo, Help and similar pharmacies may pivot to:

• HRT formulations (estradiol, progesterone, testosterone), which have a more stable compounding regulatory environment
• Peptides (BPC-157, TB-500, CJC-1295/Ipamorelin) that are not subject to the same shortage-list framework, though FDA has signaled increased scrutiny of peptide compounding
• Oral semaglutide compounding, which occupied a contested regulatory status into 2025

FDA issued specific guidance noting that oral semaglutide compounding raises distinct safety concerns because Rybelsus (oral semaglutide) uses a proprietary absorption-enhancing excipient (SNAC) that is not easily replicated in compounded formulations.

Patients relying on price-driven access to GLP-1 therapy should plan for transition to manufacturer patient assistance programs or insurance coverage pathways. Novo Nordisk's patient assistance program for Wegovy covers eligible uninsured patients who meet income thresholds, with monthly costs potentially as low as $0 to $25. That URL is not on the HealthRX allow-list; patients should confirm directly with Novo Nordisk.

Help Pharmacy Complaints: Patterns and How to Evaluate Them

Consumer complaints about Help Pharmacy fall into categories that are distinct in their clinical significance.

Operational Complaints (Lower Clinical Risk)

Shipping delays, billing errors, and customer service problems are frustrating but do not directly harm patients medically. These complaints were especially common during the 2023 demand surge when most compounders were operating at capacity. The FDA has noted that quality control during high-demand compounding periods is a specific inspection focus.

Product Quality Complaints (Higher Clinical Risk)

A smaller subset of complaints involved reports of product that appeared different in color, clarity, or precipitate compared to previous orders. These complaints raise quality-control questions. Sterile injectable products must meet USP <797> standards for beyond-use dating, sterility testing, and particulate matter. USP <797> standards for sterile compounding are the primary quality benchmark for injectable compounded drugs, as referenced in FDA guidance on 503A pharmacy oversight.

Patients who observe visible particulate matter, unexpected color changes, or altered viscosity in any injectable compounded product should not use it and should report the product to the FDA's MedWatch system.

How to File a Complaint

Patients with concerns about a compounded product can report to:

• FDA MedWatch (fda.gov/safety/medwatch)
• Their state board of pharmacy
• The pharmacy's 503B registration officer (required by DQSA)

FDA's MedWatch program is the primary mechanism for reporting adverse events and quality problems with compounded drugs.

Alternatives to Help Pharmacy for Compounded and Brand-Name GLP-1 Access

Patients seeking GLP-1 therapy in 2025 have a narrower set of legal compounding options than in 2023.

Other 503A/503B Compounders

Other registered 503B outsourcing facilities face the same legal constraints as Help following the semaglutide shortage-list removal. The FDA maintains a current list of registered 503B outsourcing facilities. Any compounding pharmacy continuing to sell compounded semaglutide after the applicable wind-down period is doing so outside the legal framework.

Manufacturer Patient Assistance

Both Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) operate patient assistance programs. Novo Nordisk's U.S. Prescribing information and savings program details for Wegovy are available through FDA-approved labeling on accessdata.fda.gov.

Step-Therapy and Insurance Pathways

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents for weight management in type 2 diabetes, which may provide a clearer insurance-coverage pathway than obesity-only indications. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.